RTW Investments LP cut its stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 23.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,506,102 shares of the company's stock after selling 750,000 shares during the period. RTW Investments LP owned approximately 4.70% of Milestone Pharmaceuticals worth $5,914,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Jones Financial Companies Lllp lifted its holdings in Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after acquiring an additional 10,000 shares during the last quarter. National Bank of Canada FI raised its holdings in shares of Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after purchasing an additional 11,600 shares in the last quarter. Northern Trust Corp boosted its holdings in Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after buying an additional 30,772 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth approximately $73,000. Finally, XTX Topco Ltd acquired a new position in Milestone Pharmaceuticals in the fourth quarter worth approximately $80,000. Institutional investors own 86.18% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on MIST shares. TD Cowen downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 1st. TD Securities downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Cowen downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Friday, March 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Milestone Pharmaceuticals presently has a consensus rating of "Hold" and an average price target of $17.00.
View Our Latest Analysis on MIST
Milestone Pharmaceuticals Trading Up 5.7%
Shares of MIST stock traded up $0.07 during trading hours on Monday, reaching $1.29. 1,043,002 shares of the stock traded hands, compared to its average volume of 891,280. Milestone Pharmaceuticals Inc. has a 1-year low of $0.63 and a 1-year high of $2.75. The business has a fifty day moving average price of $1.27 and a 200 day moving average price of $1.71. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $68.97 million, a PE ratio of -1.59 and a beta of 0.86.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). On average, equities research analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current year.
About Milestone Pharmaceuticals
(
Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
See Also
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
